Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 8/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3261417 | 0.81 | LTA4H (0.42) | ESR2LPLLIPG | |
| SCHEMBL3262944 | 0.81 | LTA4H (0.42) | ESR2LPLLIPG | |
| SCHEMBL3263042 | 0.81 | LTA4H (0.42) | ESR2LPLLIPG | |
| SCHEMBL3264000 | 0.78 | KCNA5 (0.44) | ESR2LPLLIPGF11 | |
| SCHEMBL6073275 | 0.74 | DPP4 (0.42) | OPRL1THRBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11651599 | 0.74 | OPRL1 (0.58) | OPRL1 | |
| SCHEMBL138606 | 0.72 | LPL (0.47) | LPLLIPGTP53 | |
| SCHEMBL237794 | 0.72 | ESR2 (0.50) | ESR2LPLLIPGF11 | |
| SCHEMBL31376528 | 0.72 | ESR2 (0.50) | ESR2LPLLIPGF11 | |
| SCHEMBL24933207 | 0.72 | ESR2 (0.35) | ESR2LPLLIPGF11P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |